Internship
Develops treatments for neurodegenerative diseases
$20.96 - $25.87/hr
San Bruno, CA, USA
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Denali Therapeutics focuses on developing treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, which involve the gradual loss of nerve cells leading to serious health issues. The company uses scientific research to understand the biological pathways that cause these diseases, aiming to create drugs that target specific molecules in the body. Denali stands out from competitors by combining its own research efforts with partnerships with other biotech firms and pharmaceutical companies, allowing for shared resources and knowledge. The goal of Denali Therapeutics is to create effective treatments that improve the lives of patients suffering from these debilitating conditions.
Company Size
201-500
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Denali Therapeutics opens new biomanufacturing facility in Salt Lake City.
Proficio Capital Partners LLC makes new $514,000 investment in Denali Therapeutics Inc. (NASDAQ:DNLI).
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates.
Last month, Sanofi and development partner Denali Therapeutics announced that their ALS hopeful SAR443820/DNL788, an investigational RIPK1 blocker, could not significantly improve functional performance in the Phase II HIMALAYA trial.
Denali Therapeutics announces $500 million private placement equity financing.